{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:46:09Z","timestamp":1785822369721,"version":"3.56.0"},"reference-count":126,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Social Fund\u2014Operational Program of Andalusia 2014\u20132020","award":["RH-0055-2020"],"award-info":[{"award-number":["RH-0055-2020"]}]},{"name":"European Social Fund\u2014Operational Program of Andalusia 2014\u20132020","award":["UMA20-FEDERJA-161"],"award-info":[{"award-number":["UMA20-FEDERJA-161"]}]},{"name":"European Social Fund\u2014Operational Program of Andalusia 2014\u20132020","award":["PI18\/01181"],"award-info":[{"award-number":["PI18\/01181"]}]},{"name":"European Social Fund\u2014Operational Program of Andalusia 2014\u20132020","award":["PI21\/00252"],"award-info":[{"award-number":["PI21\/00252"]}]},{"name":"University of Malaga\u2014Consejer\u00eda de Transformaci\u00f3n Econ\u00f3mica, Industria, Conocimiento y Universidades\u2014Junta de Andalucia","award":["RH-0055-2020"],"award-info":[{"award-number":["RH-0055-2020"]}]},{"name":"University of Malaga\u2014Consejer\u00eda de Transformaci\u00f3n Econ\u00f3mica, Industria, Conocimiento y Universidades\u2014Junta de Andalucia","award":["UMA20-FEDERJA-161"],"award-info":[{"award-number":["UMA20-FEDERJA-161"]}]},{"name":"University of Malaga\u2014Consejer\u00eda de Transformaci\u00f3n Econ\u00f3mica, Industria, Conocimiento y Universidades\u2014Junta de Andalucia","award":["PI18\/01181"],"award-info":[{"award-number":["PI18\/01181"]}]},{"name":"University of Malaga\u2014Consejer\u00eda de Transformaci\u00f3n Econ\u00f3mica, Industria, Conocimiento y Universidades\u2014Junta de Andalucia","award":["PI21\/00252"],"award-info":[{"award-number":["PI21\/00252"]}]},{"name":"Instituto de Salud Carlos III","award":["RH-0055-2020"],"award-info":[{"award-number":["RH-0055-2020"]}]},{"name":"Instituto de Salud Carlos III","award":["UMA20-FEDERJA-161"],"award-info":[{"award-number":["UMA20-FEDERJA-161"]}]},{"name":"Instituto de Salud Carlos III","award":["PI18\/01181"],"award-info":[{"award-number":["PI18\/01181"]}]},{"name":"Instituto de Salud Carlos III","award":["PI21\/00252"],"award-info":[{"award-number":["PI21\/00252"]}]},{"name":"European Regional Development fund","award":["RH-0055-2020"],"award-info":[{"award-number":["RH-0055-2020"]}]},{"name":"European Regional Development fund","award":["UMA20-FEDERJA-161"],"award-info":[{"award-number":["UMA20-FEDERJA-161"]}]},{"name":"European Regional Development fund","award":["PI18\/01181"],"award-info":[{"award-number":["PI18\/01181"]}]},{"name":"European Regional Development fund","award":["PI21\/00252"],"award-info":[{"award-number":["PI21\/00252"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Colorectal cancer is the third most diagnosed cancer, behind only breast and lung cancer. In terms of overall mortality, it ranks second due to, among other factors, problems with screening programs, which means that one of the factors that directly impacts survival and treatment success is early detection of the disease. Clusterin (CLU) is a molecular chaperone that has been linked to tumorigenesis, cancer progression and resistance to anticancer treatments, which has made it a promising drug target. However, it is still necessary to continue this line of research and to adjust the situations in which its use is more favorable. The aim of this paper is to review the current genetic knowledge on the role of CLU in tumorigenesis and cancer progression in general, and discuss its possible use as a therapeutic target in colorectal cancer.<\/jats:p>","DOI":"10.3390\/ijms241914641","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:42:12Z","timestamp":1695865332000},"page":"14641","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clusterin Expression in Colorectal Carcinomas"],"prefix":"10.3390","volume":"24","author":[{"given":"Teresa","family":"T\u00e9llez","sequence":"first","affiliation":[{"name":"Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of M\u00e1laga, 29010 Malaga, Spain"},{"name":"Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC), Red de Investigaci\u00f3n en Cronicidad, Atenci\u00f3n Primaria y Promoci\u00f3n de la Salud (RICAPPS), Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), 29590 Malaga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga y Plataforma en Nanomedicina\u2014IBIMA Plataforma BIONAND, 29590 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e","family":"Martin-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of M\u00e1laga, 29010 Malaga, Spain"},{"name":"Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC), Red de Investigaci\u00f3n en Cronicidad, Atenci\u00f3n Primaria y Promoci\u00f3n de la Salud (RICAPPS), Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), 29590 Malaga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga y Plataforma en Nanomedicina\u2014IBIMA Plataforma BIONAND, 29590 Malaga, Spain"},{"name":"Research and Innovation Unit, Hospital Costa del Sol, 29602 Marbella, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximino","family":"Redondo","sequence":"additional","affiliation":[{"name":"Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of M\u00e1laga, 29010 Malaga, Spain"},{"name":"Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC), Red de Investigaci\u00f3n en Cronicidad, Atenci\u00f3n Primaria y Promoci\u00f3n de la Salud (RICAPPS), Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), 29590 Malaga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga y Plataforma en Nanomedicina\u2014IBIMA Plataforma BIONAND, 29590 Malaga, Spain"},{"name":"Research and Innovation Unit, Hospital Costa del Sol, 29602 Marbella, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3759-4044","authenticated-orcid":false,"given":"Marilina","family":"Garc\u00eda-Aranda","sequence":"additional","affiliation":[{"name":"Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC), Red de Investigaci\u00f3n en Cronicidad, Atenci\u00f3n Primaria y Promoci\u00f3n de la Salud (RICAPPS), Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), 29590 Malaga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga y Plataforma en Nanomedicina\u2014IBIMA Plataforma BIONAND, 29590 Malaga, Spain"},{"name":"Research and Innovation Unit, Hospital Costa del Sol, 29602 Marbella, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0003-9969(79)90040-2","article-title":"The isolation and partial characterization of a sulphated glycoprotein from human whole saliva which aggregates strains of Streptococcus sanguis but not Streptococcus mutans","volume":"24","author":"Hogg","year":"1979","journal-title":"Arch. Oral Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1357-2725(02)00041-9","article-title":"Clusterin\/apolipoprotein J in human aging and cancer","volume":"34","author":"Trougakos","year":"2002","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0065-230X(09)04003-2","article-title":"Chapter 3: The shifting balance between CLU forms during tumor progression","volume":"104","author":"Pucci","year":"2009","journal-title":"Adv. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12035-012-8237-1","article-title":"The role of clusterin in Alzheimer\u2019s disease: Pathways, pathogenesis, and therapy","volume":"45","author":"Yu","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"15953","DOI":"10.1021\/bi002189x","article-title":"Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state","volume":"39","author":"Poon","year":"2000","journal-title":"Biochemistry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.biocel.2012.04.010","article-title":"Small heat shock proteins in cancer therapy and prognosis","volume":"44","author":"Zoubeidi","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e48255","DOI":"10.7554\/eLife.48255","article-title":"Brain clusterin protein isoforms and mitochondrial localization","volume":"8","author":"Herring","year":"2019","journal-title":"eLife"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnins.2019.00164","article-title":"Clusterin in Alzheimer\u2019s Disease: Mechanisms, Genetics, and Lessons from Other Pathologies","volume":"13","author":"Foster","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1080\/10715760600902310","article-title":"Regulation of clusterin\/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in aging and age-related diseases","volume":"40","author":"Trougakos","year":"2006","journal-title":"Free. Radic. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1038\/sj.onc.1205594","article-title":"Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression","volume":"21","author":"Bettuzzi","year":"2002","journal-title":"Oncogene"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1038\/sj.onc.1207404","article-title":"Modulation of different clusterin isoforms in human colon tumorigenesis","volume":"23","author":"Pucci","year":"2004","journal-title":"Oncogene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.cdd.4401491","article-title":"Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells","volume":"12","author":"Caccamo","year":"2005","journal-title":"Cell Death Differ."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1042\/BJ20040158","article-title":"Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45 kDa nuclear isoform of clusterin","volume":"382","author":"Caccamo","year":"2004","journal-title":"Biochem. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1074\/jbc.M209233200","article-title":"Synthesis and functional analyses of nuclear clusterin, a cell death protein","volume":"278","author":"Leskov","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/onc.2012.212","article-title":"GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer","volume":"32","author":"Li","year":"2013","journal-title":"Oncogene"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1600-0854.2007.00549.x","article-title":"Stress-Induced Retrotranslocation of Clusterin\/ApoJ into the Cytosol","volume":"8","author":"Nizard","year":"2007","journal-title":"Traffic"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000351207","article-title":"The Molecular Chaperone Apolipoprotein J\/Clusterin as a Sensor of Oxidative Stress: Implications in Therapeutic Approaches\u2014A Mini-Review","volume":"59","author":"Trougakos","year":"2013","journal-title":"Gerontology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pros.10047","article-title":"Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy","volume":"50","author":"July","year":"2002","journal-title":"Prostate"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/sj.bjc.6602193","article-title":"Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis","volume":"91","author":"Scaltriti","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1158\/0008-5472.CAN-04-0920","article-title":"Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1","volume":"64","author":"Scaltriti","year":"2004","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/bi00386a008","article-title":"Biosynthesis, and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells","volume":"26","author":"Collard","year":"1987","journal-title":"Biochemistry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cne.903340205","article-title":"Localization of sulfated glycoprotein-2\/clusterin mRNA in the rat brain by in situ hybridization","volume":"334","author":"Danik","year":"1993","journal-title":"J. Comp. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ijc.11496","article-title":"Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer","volume":"108","author":"Scaltriti","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1073\/pnas.90.2.725","article-title":"Apolipoprotein J expression at fluid-tissue interfaces: Potential role in barrier cytoprotection","volume":"90","author":"Aronow","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0065-230X(09)04002-0","article-title":"Clusterin (CLU): From one gene and two transcripts to many proteins","volume":"104","author":"Rizzi","year":"2009","journal-title":"Adv. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11154-013-9275-3","article-title":"The physiological roles of apolipoprotein J\/clusterin in metabolic and cardiovascular diseases","volume":"15","author":"Park","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/1078-0432.CCR-09-2917","article-title":"Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer","volume":"16","author":"Zoubeidi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_28","first-page":"3745","article-title":"ATM dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability. Oncogene","volume":"30","author":"Goetz","year":"2011","journal-title":"Nat. Publ. Group"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Prochnow, H., Gollan, R., Rohne, P., Hassemer, M., Koch-Brandt, C., and Baiersd\u00f6rfer, M. (2013). Non-Secreted Clusterin Isoforms Are Translated in Rare Amounts from Distinct Human mRNA Variants and Do Not Affect BaxMediated Apoptosis or the NF-\u03baB Signaling Pathway. PLoS ONE, 8.","DOI":"10.1371\/annotation\/48cea21c-d035-4757-bf42-c97028306f11"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/bj3280045","article-title":"Stress-induced transcription of the clusterin\/apoJ gene","volume":"50","author":"Michel","year":"1997","journal-title":"Biochem. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000259912","article-title":"Regulation of clusterin expression in human cancer via DNA methylation","volume":"30","author":"Serrano","year":"2009","journal-title":"Tumour Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.bbadis.2015.04.021","article-title":"Clusterin gene is predominantly regulated by histone modifications in human colon cancer and ectopic expression of the nuclear isoform induces cell death","volume":"1852","author":"Deb","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1677\/jme.0.0130069","article-title":"Regulators for the rat clusterin gene: DNA methylation and cis-acting regulatory elements","volume":"13","author":"Rosemblit","year":"1994","journal-title":"J. Mol. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1158\/1535-7163.223.3.3","article-title":"Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo","volume":"3","author":"July","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4149\/neo_2010_03_191","article-title":"Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: A study on tissue microarrays","volume":"57","author":"Bi","year":"2010","journal-title":"Neoplasm"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cncr.20765","article-title":"Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma","volume":"103","author":"Xie","year":"2005","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0002-9440(10)64552-X","article-title":"Overexpression of clusterin in human breast carcinoma","volume":"157","author":"Redondo","year":"2000","journal-title":"Am. J. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0065-230X(09)05002-7","article-title":"The role of clusterin (CLU) in malignant transformation and drug resistance in breast carcinomas","volume":"105","author":"Redondo","year":"2009","journal-title":"Adv. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0065-230X(09)05003-9","article-title":"CLU and colon cancer. The dual face of CLU: From normal to malignant phenotype","volume":"105","author":"Mazzarelli","year":"2009","journal-title":"Adv. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/j.1365-2559.2010.03565.x","article-title":"Clusterin expression is associated with decreased disease-free survival of patients with colorectal carcinomas","volume":"56","author":"Redondo","year":"2010","journal-title":"Histopathology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0090-4295(01)01484-4","article-title":"Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence","volume":"59","author":"Miyake","year":"2002","journal-title":"Urology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1038\/s41598-021-94330-1","article-title":"The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma","volume":"11","author":"Patarat","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00006676-200210000-00004","article-title":"Expression of clusterin in human pancreatic cancer","volume":"25","author":"Xie","year":"2002","journal-title":"Pancreas"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.0022-202X.2005.23720.x","article-title":"Clusterin regulates drug-resistance in melanoma cells","volume":"124","author":"Hoeller","year":"2005","journal-title":"J. Investig. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1111\/j.1349-7006.2009.01349.x","article-title":"Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma","volume":"100","author":"He","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V96.2.398.014k46_398_404","article-title":"Detection of differentially expressed genes in lymphomas using cDNA arrays: Identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas","volume":"96","author":"Wellmann","year":"2000","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/21655979.2019.1621136","article-title":"sCLU as prognostic biomarker and therapeutic target in osteosarcoma","volume":"10","author":"Ma","year":"2019","journal-title":"Bioengineered"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(09)05001-5","article-title":"Clusterin (CLU) and prostate cancer","volume":"105","author":"Rizzi","year":"2009","journal-title":"Adv. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Praharaj, P.P., Patra, S., Panigrahi, D.P., Patra, S.K., and Bhutia, S.K. (2021). Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy. Biochim. Biophys. Acta Rev. Cancer, 1875.","DOI":"10.1016\/j.bbcan.2020.188500"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13046-021-01934-6","article-title":"Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt\/\u03b2-catenin pathway","volume":"40","author":"Liu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"36728","DOI":"10.18632\/oncotarget.13574","article-title":"CARESS-CCR Study Group. Factors that influence treatment delay in patients with colorectal cancer","volume":"8","author":"Rueda","year":"2017","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Padilla-Ruiz, M., Morales-Su\u00e1rez-Varela, M., Rivas-Ruiz, F., Alcaide, J., Varela-Moreno, E., Zarcos-Pedrinaci, I., T\u00e9llez, T., Fern\u00e1ndez-de Larrea-Baz, N., Bar\u00e9, M., and Bilbao, A. (2022). On Behalf of Caress\u2013Ccr Study Group. Influence of Diagnostic Delay on Survival Rates for Patients with Colorectal Cancer. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19063626"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.giec.2021.12.008","article-title":"Risk Factors for Colorectal Polyps and Cancer","volume":"32","author":"Sninsky","year":"2022","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1101\/gad.348226.120","article-title":"Genetic and biological hallmarks of colorectal cancer","volume":"35","author":"Li","year":"2021","journal-title":"Genes Dev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.10.035","article-title":"Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management","volume":"162","author":"Shah","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3322\/caac.21728","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.giec.2021.12.001","article-title":"Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer","volume":"32","author":"Sullivan","year":"2022","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Silva, A.L., Dawson, S.N., Arends, M.J., Guttula, K., Hall, N., Cameron, E.A., Huang, T.H., Brenton, J.D., Tavar\u00e9, S., and Bienz, M. (2014). Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-891"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2559.2006.02549.x","article-title":"Classification of colorectal cancer based on correlation of clinical, morphological, and molecular features","volume":"50","author":"Jass","year":"2007","journal-title":"Histopathology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/his.12055","article-title":"The serrated pathway to colorectal carcinoma: Current concepts and challenges","volume":"62","author":"Bettington","year":"2013","journal-title":"Histopathology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/annonc\/mdy337","article-title":"Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2","volume":"29","author":"Chang","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.1073\/pnas.96.15.8681","article-title":"CpG island methylator phenotype in colorectal cancer","volume":"96","author":"Toyota","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/321209a0","article-title":"CpG-rich islands and the function of DNA methylation","volume":"321","author":"Bird","year":"1986","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"102325","DOI":"10.1016\/j.ctrv.2021.102325","article-title":"A comprehensive overview of tumor deposits in colorectal cancer: Towards a next TNM classification","volume":"103","author":"Delattre","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Cervantes","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/crc-2017-0007","article-title":"New insights into colorectal cancer screening and early detection tests","volume":"6","author":"Kormi","year":"2017","journal-title":"Color. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nbt.3221","article-title":"Precision medicine and the FDA\u2019s draft guidance on laboratory-developed tests","volume":"33","author":"Hwang","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3389\/fimmu.2020.01624","article-title":"Colorectal Cancer Immunotherapy: Options and Strategies","volume":"11","author":"Johdi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/DCR.0000000000001058","article-title":"Phase II Clinical Trial to Evaluate the Efficacy of Transanal Endoscopic Total Mesorectal Excision for Rectal Cancer","volume":"61","author":"Park","year":"2018","journal-title":"Dis. Colon Rectum"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1200\/JCO.18.00032","article-title":"Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients with Low cT3\/4 Rectal Cancer","volume":"37","author":"Ogura","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbrc.2003.09.170","article-title":"Photofrin as a radiosensitizer in an in vitro cell survival assay","volume":"311","author":"Kulka","year":"2003","journal-title":"Biochem. Biography. Jt. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"15065","DOI":"10.1038\/nrdp.2015.65","article-title":"Colorectal cancer","volume":"1","author":"Kuipers","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/ja01573a087","article-title":"The Synthesis of 5-Fluoropyrimidines","volume":"79","author":"Duschinsky","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic Cell Death in Cancer Therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of Patients with Advanced Colorectal Cancer Improves with the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"784336","DOI":"10.3389\/fimmu.2021.784336","article-title":"Good Tumor Response to Chemoradioimmunotherapy in dMMR\/MSI-H Advanced Colorectal Cancer: A Case Series","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR Antagonists in Cancer Treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_86","first-page":"CD007047","article-title":"Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer","volume":"6","author":"Chan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","article-title":"Targeting the EGFR signaling pathway in cancer therapy: What\u2019s new in 2023?","volume":"27","author":"Halder","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/0008-5472.CAN-17-2084","article-title":"KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment","volume":"78","author":"Cardoso","year":"2018","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer Type","volume":"384","author":"Nassar","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1200\/JCO.21.02541","article-title":"BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape","volume":"40","author":"Ciombor","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jnci\/djab042","article-title":"BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data from the ARCAD Database","volume":"113","author":"Cohen","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1038\/s41467-018-05226-0","article-title":"A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer","volume":"9","author":"Saito","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/bjc.2011.201","article-title":"XELOX vs. FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results","volume":"105","author":"Cassidy","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2010.32.5977","article-title":"Randomized Phase II Trial of Adjuvant Hepatic Arterial Arterial Infusion and Systemic Chemotherapy with or without Bevacizumab in Patients with Resected Hepatic Metastases from Colorectal Cancer","volume":"29","author":"Kemeny","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Eastern Cooperative Oncology Group Study E3200. Bevacizumab in Combination with Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1158\/1078-0432.CCR-11-3252","article-title":"Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer","volume":"18","author":"Tang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.32163","article-title":"Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer","volume":"125","author":"Piawah","year":"2019","journal-title":"Cancer"},{"key":"ref_99","first-page":"95","article-title":"The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer","volume":"11","author":"Yarom","year":"2011","journal-title":"Discov. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1158\/1078-0432.CCR-19-0823","article-title":"Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies","volume":"25","author":"Parseghian","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and Treatment of Metastatic Colorectal Cancer","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","article-title":"Phase I Dose\u2014Escalation and Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF\u2014Mutant Melanoma","volume":"23","author":"Delord","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/djz093","article-title":"Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches","volume":"111","author":"Franke","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardollm","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1002\/eji.200526347","article-title":"PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion","volume":"35","author":"Saunders","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1586\/14737140.2016.1170594","article-title":"Update on optimal treatment for metastatic colorectal cancer from the ACTG\/AGITG expert meeting: ECCO 2015","volume":"16","author":"Price","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1084\/jem.20141308","article-title":"Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity","volume":"211","author":"Duan","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11888-015-0258-5","article-title":"Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer","volume":"11","author":"Segal","year":"2015","journal-title":"Curr. Colorectal Cancer Rep."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Bertuzzi, M., Marelli, C., Bagnati, R., Colombi, A., Fanelli, R., Saieva, C., Ceroti, M., Bendinelli, B., Caini, S., and Airoldi, L. (2015). Plasma clusterin as a candidate prediagnostic marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: A pilot study. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1058-7"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clinbiochem.2019.10.008","article-title":"High levels of clusterin mRNA (CLU) expression in tumors of colorectal cancer patients predict poor prognostic outcome","volume":"75","author":"Artemaki","year":"2020","journal-title":"Clin. Biochem."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kopylov, A.T., Stepanov, A.A., Malsagova, K.A., Soni, D., Kushlinsky, N.E., Enikeev, D.V., Potoldykova, N.V., Lisitsa, A.V., and Kaysheva, A.L. (2020). Unveiling proteomic markers for early-stage colorectal cancer. Molecules, 25.","DOI":"10.3390\/molecules25030619"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.onc.1204148","article-title":"Tumor specific modulation of Ku70\/80 DNA binding activity in breast and bladder human tumor biopsies","volume":"20","author":"Pucci","year":"2001","journal-title":"Oncogene"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/cncr.10807","article-title":"The expression pattern of Ku correlates with tumor radiosensitivity and disease-free survival in patients with rectal carcinoma","volume":"95","author":"Komuro","year":"2002","journal-title":"Cancer"},{"key":"ref_118","first-page":"223","article-title":"Prediction of tumor radiosensitivity in rectal carcinoma based on p53 and Ku70 expression","volume":"22","author":"Komuro","year":"2003","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.3748\/wjg.v11.i42.6694","article-title":"DNA end binding activity and Ku70\/80 heterodimer expression in human colorectal tumor","volume":"11","author":"Mazzarelli","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijrobp.2016.10.018","article-title":"Ku70, Ku80, and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation Therapy in Patients with Locally Advanced Rectal Cancer","volume":"97","author":"Pucci","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12029-011-9277-x","article-title":"Clusterin and chemotherapy sensitivity under normoxic and graded hypoxic conditions in colorectal cancer","volume":"43","author":"Kevans","year":"2012","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Engel, R.M., Chan, W.H., Nickless, D., Hlavca, S., Richards, E., Kerr, G., Oliva, K., McMurrick, P.J., Jard\u00e9, T., and Abud, H.E. (2020). Patient-Derived Colorectal Cancer Organoids Upregulate Revival Stem Cell Marker Genes following Chemotherapeutic Treatment. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010128"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41598-023-29948-4","article-title":"A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer","volume":"13","author":"Grosgeorges","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/ijc.28910","article-title":"A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer","volume":"135","author":"Vieito","year":"2014","journal-title":"Int. J. Cancer."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Insua, Y.V., C\u00e1mara, J., V\u00e1zquez, E.B., Fern\u00e1ndez, A., Rivera, F.V., Silva, M.J.V.V., Barbaz\u00e1n, J., Muinelo-Romay, L., Folgar, S.C., and Abalo, A. (2017). Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18061265"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"9408839","DOI":"10.1155\/2022\/9408839","article-title":"Construction of a Colorectal Cancer Prognostic Risk Model and Screening of Prognostic Risk Genes Using Machine-Learning Algorithms","volume":"2022","author":"Du","year":"2022","journal-title":"Comput. Math Methods Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/19\/14641\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:59:48Z","timestamp":1760129988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/19\/14641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":126,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["ijms241914641"],"URL":"https:\/\/doi.org\/10.3390\/ijms241914641","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}